(Q36540286)

14 August 2017

1 reference

title

Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults (English)

1 reference

14 August 2017

1

Richard B Lanman

1 reference

14 August 2017

Robert L Wolfert

2

1 reference

14 August 2017

James K Fleming

3

1 reference

14 August 2017

Allan S Jaffe

4

1 reference

14 August 2017

William L Roberts

5

1 reference

14 August 2017

G Russell Warnick

6

1 reference

14 August 2017

Joseph P McConnell

7

1 reference

14 August 2017

language of work or name

1 reference

1 January 2006

1 reference

14 August 2017

published in

Preventive Cardiology

1 reference

14 August 2017

volume

9

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

138-143

1 reference

Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2006.05547.X

Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2006.05547.X

A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2006.05547.X

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2006.05547.X

Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2006.05547.X

Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2006.05547.X

Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infar

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2006.05547.X

Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2006.05547.X

Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2006.05547.X

Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2006.05547.X

Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2006.05547.X

Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2006.05547.X

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2006.05547.X

10.1111/J.1520-037X.2006.05547.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference